High prevalence of OXA-143 and alteration of outer membrane proteins in carbapenem-resistant Acinetobacter spp. isolates in Brazil

Carregando...
Imagem de Miniatura
Citações na Scopus
51
Tipo de produção
article
Data de publicação
2012
Editora
ELSEVIER SCIENCE BV
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, v.39, n.5, p.396-401, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Carbapenem resistance amongst Acinetobacter spp. has been increasing in the last decade. This study evaluated the outer membrane protein (OMP) profile and production of carbapenemases in 50 carbapenem-resistant Acinetobacter spp. isolates from bloodstream infections. Isolates were identified by API20NE. Minimum inhibitory concentrations (MICs) for carbapenems were determined by broth microdilution. Carbapenemases were studied by phenotypic tests, detection of their encoding gene by polymerase chain reaction (PCR) amplification, and imipenem hydrolysis. Nucleotide sequencing confirming the enzyme gene type was performed using MegaBACE 1000. The presence of OMPs was studied by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and PCR. Molecular typing was performed using pulsed-field gel electrophoresis (PFGE). All isolates were resistant to carbapenems. Moreover, 98% of the isolates were positive for the gene encoding the enzyme OXA-51-like, 18% were positive for OXA-23-like (only one isolate did not show the presence of the insertion sequence ISAba1 adjacent to this gene) and 76% were positive for OXA-143 enzyme. Five isolates (10%) showed the presence of the IMP-1 gene. Imipenem hydrolysing activity was detected in only three strains containing carbapenemase genes, comprising two isolates containing the bla(IMP) gene and one containing the bla(OXA-51/OXA-23-like) gene. The OMP of 43 kDa was altered in 17 of 25 strains studied, and this alteration was associated with a high meropenem MIC (256 mu g/mL) in 5 of 7 strains without 43 kDa OMP. On the other hand, decreased OMP 33-36 kDa was found in five strains. The high prevalence of OXA-143 and alteration of OMPs might have been associated with a high level of carbapenem resistance.
Palavras-chave
Carbapenem resistance, Acinetobacter, OXA-143, Outer membrane protein
Referências
  1. Antonio CS, 2011, ANTIMICROB AGENTS CH, V55, P1322, DOI 10.1128/AAC.01102-10
  2. Bou G, 2000, J CLIN MICROBIOL, V38, P3299
  3. Bratu S, 2008, ANTIMICROB AGENTS CH, V52, P2999, DOI 10.1128/AAC.01684-07
  4. Carvalho KR, 2009, INT J ANTIMICROB AG, V34, P25, DOI 10.1016/j.ijantimicag.2008.12.009
  5. Clark RB, 1996, J ANTIMICROB CHEMOTH, V38, P245, DOI 10.1093/jac/38.2.245
  6. Clinical and Laboratory Standards Institute, 2011, M100S21 CLSI
  7. Dupont M, 2005, J PROTEOME RES, V4, P2386, DOI 10.1021/rp050143q
  8. Fernandez-Cuenca F, 2003, J ANTIMICROB CHEMOTH, V51, P565, DOI 10.1093/jac/dkg097
  9. Gales AC, 2004, MICROB DRUG RESIST, V10, P286, DOI 10.1089/mdr.2004.10.286
  10. Higgins PG, 2010, J ANTIMICROB CHEMOTH, V65, P233, DOI 10.1093/jac/dkp428
  11. Higgins PG, 2009, ANTIMICROB AGENTS CH, V53, P5035, DOI 10.1128/AAC.00856-09
  12. Hu WS, 2007, ANTIMICROB AGENTS CH, V51, P3844, DOI 10.1128/AAC.01512-06
  13. Huang L, 2008, DIAGN MICR INFEC DIS, V62, P326, DOI 10.1016/j.diagmicrobio.2008.06.008
  14. Jeong HW, 2009, MICROB DRUG RESIST, V15, P151, DOI 10.1089/mdr.2009.0828
  15. Lee BK, 2001, CLIN MICROBIOL INFEC, V7, P88
  16. Limansky AS, 2002, J CLIN MICROBIOL, V40, P4776, DOI 10.1128/JCM.40.12.4776-4778.2002
  17. Lin YC, 2010, INT J ANTIMICROB AG, V35, P439, DOI 10.1016/j.ijantimicag.2009.11.020
  18. Lu PL, 2009, J ANTIMICROB CHEMOTH, V63, P641, DOI 10.1093/jac/dkn553
  19. Mostachio Anna Karina, 2009, J Med Microbiol, V58, P1522, DOI 10.1099/jmm.0.011080-0
  20. Mussi MA, 2005, ANTIMICROB AGENTS CH, V49, P1432, DOI 10.1128/AAC.49.4.1432-1440.2005
  21. Pournaras S, 2006, J ANTIMICROB CHEMOTH, V57, P557, DOI 10.1093/jac/dkl004
  22. Sader HS, 2005, INT J ANTIMICROB AG, V25, P57, DOI 10.1016/j.ijantimicag.2004.08.013
  23. Siroy A, 2005, ANTIMICROB AGENTS CH, V49, P4876, DOI 10.1128/AAC.49.12.4876-4883.2005
  24. Sole M, 2011, ANTIMICROB AGENTS CH, V55, P4402, DOI 10.1128/AAC.00642-11
  25. TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233
  26. Werneck JS, 2011, ANTIMICROB AGENTS CH, V55, P4494, DOI 10.1128/AAC.00295-11
  27. Yang SC, 2010, EUR J CLIN MICROBIOL, V29, P601, DOI 10.1007/s10096-010-0878-2
  28. Zarrilli R, 2007, CLIN MICROBIOL INFEC, V13, P481, DOI 10.1111/j.1469-0691.2006.01675.x